AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 AUG 20 - (NewsRx.com & NewsRx.net) -- Cobra Biomanufacturing has announced an agreement with Advaxis, Inc., to supply clinical trials and, potentially, commercial supplies of the active ingredient for its Listeria monocytogenes-based cancer vaccine. This is Advaxis' leading product due to start clinical trials as a cervical cancer treatment within the next 12 months.
Research done in the laboratory of Yvonne Paterson PhD, scientific founder of Advaxis, demonstrates that an attenuated form of the bacterium Listeria can effectively induce the body's immune system to fight cancer.
J. Todd Derbin, chief executive of Advaxis, said, "We selected Cobra after a thorough evaluation of all aspects of their capabilities in GMP biologics manufacturing to the highest quality standards. It is very important to Advaxis to be working with a CMO that manufactures to U.S. and European regulatory standards, and offers us multiple options in the planning of ...
Source: HighBeam Research, Novel vaccine to be manufactured from live bacterium.